Lehrer-Graiwer Joshua 4

What Happened

• Joshua Lehrer-Graiwer, a director of Fulcrum Therapeutics (FULC), received a grant of 64,000 derivative shares (an option/award) on April 23, 2026. The grant is reported at an acquisition price of $0.00 (no cash paid at grant); the Form 4 lists the transaction as an award/other acquisition.

Key Details

• Transaction date: 2026-04-23; Filing date (Form 4): 2026-05-01 — the filing was submitted more than the typical two-business-day window after the transaction.
• Amount: 64,000 derivative shares; reported acquisition price: $0.00; reported total value at grant: $0 (derivative).
• Shares owned after transaction: not specified in the provided report.
• Footnote: The option was granted April 23, 2026 and vests in equal monthly installments until April 23, 2029, subject to continued service.
• No indication of a sale, exercise, tax withholding, or 10b5-1 plan in this filing.

Context

• This is a compensation-related award (an option/derivative grant) rather than an open-market purchase or sale. Such grants compensate or retain insiders and do not by themselves signal a buy/sell decision. If and when options are exercised or shares are sold, separate filings (Forms 4) would report those transactions.